Q2 2026 revenue grew 11% year-over-year to $202 million, with clinical services up 14% and NGS revenue up 26%. Adjusted EBITDA rose 36% to $14 million, and full-year guidance was raised for both revenue and EBITDA. Net income reached $2 million, reversing a prior-year loss.Original document: NeoGen…
Q2 2026 revenue grew 11% year-over-year to $202 million, with clinical services up 14% and NGS revenue up 26%. Adjusted EBITDA rose 36% to $14 million, and full-year guidance was raised for both revenue and EBITDA. Net income reached $2 million, reversing a prior-year loss.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
